HG34-mutant gliomas

H3G34-mutant gliomas are rare but aggressive pediatric diffuse high-grade gliomas with a median survival time of just 18-22 months (37509641). These gliomas typically feature missense mutations within the histone gene H3F3A, resulting in very poor prognosis in pediatric populations. While H3G34-mutant gliomas have been studied histologically in the past, very few papers have explored how different mutations can impact the prognostic outcomes, treatment successes, and overall survival of these patients.
 
In this proposed retrospective study, we aim to better characterize the genomic underpinnings of H3G34-mutant gliomas to determine 1) the correlation between different mutation types and patient outcomes, 2) the correlation between mutations and imaging and pathological findings, and 3) determine co-occurring genetic alterations. We hope to elucidate these questions by accessing the patient outcomes, molecular/genomic studies, imaging files, and histopathological data of CBTN’s H3G34-mutant glioma cohort. Each patient’s demographics, treatment course, co-morbidities, overall survival, tumor genetic alterations, and characteristics will be recorded. The Cox proportional hazards model will be used to perform multivariate analysis to determine statistically significant variables in clinical outcomes. Additionally, Kaplan Meier survival analysis will be completed and compared by log-rank test. We hope to share our results by publishing our work at the end of the study.
 
Given the rarity of H3G34-mutant gliomas, there is no standard of care for these tumors and the current literature has significant gaps in the prognostic features of these patients. This study can help highlight the key genetic alterations that influence patient outcomes, thereby informing clinical decision-making and guiding the development of targeted therapies. CBTN offers one of the largest repositories for H3G34-mutant gliomas, which we hope to use to address this research gap.